# Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer

> **NCT07088263** · PHASE3 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 192 (estimated)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Gemcitabine, Vinorelbine, Eribulin, or Utidelone

## Key facts

- **NCT ID:** NCT07088263
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-15
- **Primary completion:** 2027-07-24
- **Final completion:** 2028-06-24
- **Target enrollment:** 192 (ESTIMATED)
- **Last updated:** 2025-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07088263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07088263, "Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07088263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*